The Swiss city of Basel has put a hold on the launch of ‘Weed Care’, Europe’s first recreational cannabis trial, due to concerns over product ‘quality standards’. Source cannabis analysis has found0.1-0.2 parts per million of fluopyram, a pesticide not certified for organic cultivation. ‘Organic’ was part of the legal stipulation for the study’s approval. This production protocol subjects the purity of the harvested cannabis to environmental variables, like soil contaminants, and pesticide residue. Lino Cereghetti, chief operating officer of Pure Production AG, supplier of the source cannabis, suggests that there may be reasonable warrant for review of the experimental statute governing this study. The quantity of fluopyram found in the assay are well within the acceptable range for ordinary produce. Part of the function of pilot studies like this, he observes, besides establishing real-world benefits data, is to judge to what degree studies in general may be over-regulated.
The problem of purity, and its sibling problem, consistency, are unavoidable in agriculture-based production. Industrial assembly of cannabinoids by synthetic means bypasses this. Using non-cannabis source material obviates any need for testing for THC content in pharmaceutical or practitioner-grade products as well. If THC is required in a product, as in the case of the Weed Care study, this too can be managed without a cannabis precursor, and the amounts can be assured with precision. These techniques are fully scalable, moreover, and do not rely on harvesters’ success with yearly crop yields.
PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at310-666-4869, or email@example.com.
The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.
Promotions, new products and sales. Directly to your inbox.